4Khan IA,Nair CK,Singh N,et al.Acute ventricular rate control in atrial fibrillation and atrial flutter[J].Int J Cardiol,2004,97(1):7-13.
5The DAAF Group.Intravenous digoxin in acute atrial fibrillation:results of a randomized,placebo-controlled multicentre trial in 239 patients[J].Eur Heart J,1997,18:649-654.
6Roberts SA,Diaz C,Nolan PE,et al.Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter[J].Am J Cardiol,1993,72:567-573.
7Agarwal A,York M,Kantharia B,et al.Atrial fibrillation:concepts and management[J].Annu Rev Med,2005,65:475-494.
8Falk RH,Kn wlton AA,Bernard SA,et al.Digoxin for converting recent-onset atrial fibrillation to sinus rhythm:a randomized,double-blind trial[J].Ann Intern Med,1987,106:503-506.
9Lo GK,Fatovich DM,Haig AD.Biphasic cardioversion of acute atrial fibrillation in the emergency department[J].Emerg Med J,2006,Jan,23(1):51-53.
10Falk RH.Proarrhythmia in patients treated for atrial fibrillation or flutter[J].Ann Intern Med,1992,117:141-150.
2Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications[J]. Arch Intern Med, 1995,155:469-473.
3Wattigney WA, Mensah GA, Croft JB. Increasing Trends in Hospitalization for Atrial Fibrillation in the United States, 1985 Through 1999 Implications for Primary Prevention[J]. Circulation,2003,108:711-716.
4Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness[J]. BMJ, 2000,320:1236-1239.
5Gage BF, Boechler M , Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation[J].Stroke ,2000,31:822-827.
6SPORTIF Ⅲ investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF Ⅲ): randomized controlled trial[J]. Lancet, 2003,362:1691-1698.
7Halperin JL. Efficacy and safety study of oral direct thromnin inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation: SPORTIFⅤ[R]. American Heart Association Scientific Sessions, Orlando, USA, November, 2003.
8Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation[J]. Circulation, 2002,105:1077-1081.
9Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: Outcomes from a controlled nonrandomized long-term study[J]. J Am Coll Cardiol ,2003,42:185-197.
10Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study[J]. Circulation, 1998,98:946-952.
